CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Transition of Macrophages to Fibroblast-Like Cells in Healing Myocardial Infarction Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation Discharge Against Medical Advice After Percutaneous Coronary Intervention in the United States 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Management of Percutaneous Coronary Intervention Complications: Algorithms From the 2018 and 2019 Seattle Percutaneous Coronary Intervention Complications Conference Percutaneous Coronary Intervention for Chronic Total Occlusion—The Michigan Experience: Insights From the BMC2 Registry

Guideline2019 Jan 28. pii: S1547-5271(19)30037-2.

JOURNAL:Heart Rhythm. Article Link

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

January CT, Wann LS, Calkins H et al. Keywords: acute coronary syndrome; anticoagulants; antiplatelet agents; apixaban; atrial fibrillation; atrial flutter; coronary artery disease; dabigatran; edoxaban; idarucizumab; warfarin;

FULL TEXT PDF